骨髓增生异常综合征治疗进展

Treatment progress of myelodysplastic syndromes

骨髓增生异常综合征(MDS)的有效治疗方式非常有限,主要根据个体化差异和不同的风险等级(通过修订的国际预后评分系统)制定患者的治疗方案,包括随访观察、红系造血刺激剂治疗、祛铁治疗、免疫抑制剂治疗、来那度胺治疗、去甲基化治疗和造血干细胞移植(HSCT)等。治疗策略的局限性是未来临床试验重要的探索方向,目前关于治疗MDS的多个临床试验尚在进行中,但仍有必要对MDS的分子和遗传数据进行整合,运用到临床实践中来优化治疗方法。文章对MDS目前的治疗方案进行综述,并对未来的研究方向进行了展望。

The effective treatment methods of myelodysplastic syndromes(MDS)are limited.The patient's treatment plan is mainly based on individual differences and different risk levels[by revised International Prognostic Points System(IPSS-R)],including observation,erythropoiesis stimulating agents,iron elimination,immunosuppressive agents,lenalidomide,hypomethylating agents and hematopoietic stem cell transplantation(HSCT).The limitations of the treatment strategies are important exploration directions for future clinical trials.At present,multiple clinical trials for the treatment of MDS are underway,but it is still necessary to optimize therapies through integrating molecular and genetic data and applying them to clinical practice.This article reviews the current treatment approaches of MDS and looks forward to future research directions.